Jefferies & Company Inc. Raises Estimates And Price Target For POZEN Inc. (POZN)

Analysts at Jefferies & Company Inc. have released an update on POZEN Inc. (NASDAQ: POZN). On Friday, the FDA approved the company’s Vimovo. Analysts believe that timely regulatory approval of Vimovo is a surprise as they were expecting a regulatory delay.

Following the approval, analysts have raised their estimates for POZEN, as they had not assumed Vimovo-related revenues in their previous estimates. For 2010, analysts have raised their revenue estimate from $27.9 million to $48.4 million, for 2011, it has been raised from $26.5 million to $33.9 million, and for 2012, it has been raised from $27.2 million to $38.8 million. The price target for the company has been raised from $5 to $10.

Analysts at Jefferies & Company Inc. have maintained their Underperform rating for POZEN Inc.